A phase I study of Triapine® in combination with doxorubicin in patients with advanced solid tumors

William R. Schelman,Sherry Morgan-Meadows,Rebecca Marnocha,Fred T. Lee,Jens C. Eickhoff,Wei Huang,Marcia Pomplun,Zhisheng Jiang,Dona Alberti,Jill M. Kolesar,Percy Ivy,George Wilding,Anne M. Traynor

A phase I study of Triapine® in combination with doxorubicin in patients with advanced solid tumors

2009

William R. Schelman
Sherry Morgan-Meadows
Rebecca Marnocha
Fred T. Lee
Jens C. Eickhoff
Wei Huang
Marcia Pomplun
Zhisheng Jiang
Dona Alberti
Jill M. Kolesar
Percy Ivy
George Wilding
Anne M. Traynor

Purpose To assess the maximum-tolerated dose (MTD), dose-limiting toxicity (DLT), pharmacokinetics and antitumor activity of Triapine® administered in combination with doxorubicin.

Keywords:

Oncology
3-Aminopyridine-2-carboxaldehyde thiosemicarbazone
Cancer
Doxorubicin
Prostate cancer
Febrile neutropenia
Pharmacology
Immunology
Internal medicine
Toxicity
Pharmacokinetics
Medicine
Enzyme inhibitor
in patient
phase i study

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations